Related Experiment Video
Updated: May 29, 2026

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
Published on: September 25, 2018
[Tm analysis method using a quenching probe is a simple and rapid way to simultaneously detect KRAS and BRAF
1Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Kitaadachi-gun, Saitama-pref. 362-0806, Japan. Akagi@cancer-c.pref.saitama.jp
Abstract:
Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that, on ligand binding, triggers the RAS-RAF-MAPK signaling pathway which is mainly associated with cell proliferation. Drugs targeting EGFR have recently entered clinical practice and have proven to be effective in providing clinical benefits. However, the presence of mutated KRAS alleles in cancer is a predictive marker of anti-EGFR drug resistance. Similarly, alterations of other members of the RAS-RAF-MAPK signaling pathway may also be such predictive markers, especially the BRAF mutation in colorectal cancer. Therefore, the identification of KRAS and BRAF mutations may be important in predicting resistance to EGFR-targeted therapies. We looked at the Tm analysis for simultaneous detection of KRAS and BRAF mutations using a quenching probe. The oligonucleotide probes modified with certain fluorescent dyes at 5'-end cytosine are quenched by their interaction with a uniquely positioned guanine. When the probe is hybridized with target DNA, its fluorescence is quenched by the guanine in the target DNA. However, as the temperature is raised, perfect match probes and miss match probes dissociate at different temperatures. Dissociated probes generate fluorescence. This simple and rapid method for simultaneous detection of these mutations is useful in clinical practice.
Insights
Detecting KRAS and BRAF mutations is key to predicting resistance to epidermal growth factor receptor (EGFR)-targeted therapies. A novel Tm analysis method allows for the simultaneous detection of these mutations, aiding clinical decisions.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) signaling pathways are crucial for cell proliferation.
- EGFR-targeted therapies offer clinical benefits but face resistance.
- Mutations in KRAS and BRAF predict resistance to EGFR-targeted drugs, particularly in colorectal cancer.
Purpose of the Study:
- To develop a method for simultaneous detection of KRAS and BRAF mutations.
- To identify predictive markers for resistance to EGFR-targeted therapies.
Main Methods:
- Utilized Tm analysis with a quenching probe for simultaneous KRAS and BRAF mutation detection.
- Oligonucleotide probes with 5'-end fluorescent dyes interact with guanine for quenching.
- Differential probe dissociation temperatures at varying heat identify mutations.
Main Results:
- A simple and rapid method for simultaneous KRAS and BRAF mutation detection was established.
- The method relies on fluorescence changes upon probe dissociation at specific temperatures.
- This technique aids in predicting resistance to EGFR-targeted therapies.
Conclusions:
- Simultaneous detection of KRAS and BRAF mutations is important for predicting resistance to EGFR-targeted therapies.
- The developed Tm analysis method is a valuable tool for clinical practice.
- This approach can guide treatment decisions in oncology.
